Letters to the Editor



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

Am Fam Physician. 2003 Mar 15;67(6):1189-1190.

Update on Prescribing Information for Pantoprazole

to the editor: This letter is in response to the article, “Proton Pump Inhibitors: An Update.”1 Pantoprazole (Protonix) was approved by the U.S. Food and Drug Administration (FDA) for the acute treatment of erosive esophagitis in February 2000 and for the maintenance of healing of erosive esophagitis in June 2001.2 Additionally, both oral and intravenous formulations received approval by the FDA for the treatment of pathologic hypersecretory conditions.2,3

The article1 contained a few inaccuracies in the review of drug interactions for pantoprazole. In the review,1 pantoprazole was documented to have an unknown effect on clarithromycin (Biaxin) and increase the absorption of digoxin and nifedipine (Procardia). As per the current prescribing information, pantoprazole has no clinically relevant drug interactions with clarithromycin, digoxin, or nifedipine.2,3 We have provided this information so that your readers have the most accurate information on pantoprazole.

REFERENCES

1. Vanderhoff BT, Tahboub RM. Proton pump inhibitors: an update. Am Fam Physician. 2002;66:273–80.

2. Protonix delayed-release tablets. Package insert. Wyeth-Ayerst Pharmaceuticals. Philadelphia, Pa.: 2002. Retrieved February 2003, from www.wyeth.com/content/ShowFile.asp?id=135.

3. Protonix IV for injection. Package insert. Wyeth-Ayerst Pharmaceuticals. Philadelphia, Pa.: 2002. Retrieved February 2003, from www.wyeth.com/content/ShowFile.asp?id=136.

in reply: We appreciate the comments of Dr. Karlstadt and Ms. Walker concerning the drug interactions for pantoprazole (Protonix). In our article,1 pantoprazole was noted to have an unknown effect on clarithromycin (Biaxin) and to increase the absorption of digoxin and nifedipine (Procardia) based on information in two articles.2,3 These interactions may not be clinically relevant as is mentioned in the package insert for pantoprazole. Nevertheless, we believed it is prudent to share this information with family physicians who are frequently faced with the daunting task of managing a patient who is receiving a large number of medications, often in clinical situations unlike those typically included in drug trials.

REFERENCES

1. Vanderhoff BT, Tahboub RM. Proton pump inhibitors: an update. Am Fam Physician. 2002;66:273–80.

2. Welage LS, Berardi RR. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. J Am Pharm Assoc (Wash). 2000;40:52–62.

3. Reilly JP. Safety profile of the proton-pump inhibitors. Am J Health Syst Pharm. 1999;56(23 Suppl 4):S11–7.

Send letters to Kenneth W. Lin, MD, MPH, Associate Deputy Editor for AFP Online, e-mail: afplet@aafp.org, or 11400 Tomahawk Creek Pkwy., Leawood, KS 66211-2680.

Please include your complete address, e-mail address, and telephone number. Letters should be fewer than 400 words and limited to six references, one table or figure, and three authors.

Letters submitted for publication in AFP must not be submitted to any other publication. Possible conflicts of interest must be disclosed at time of submission. Submission of a letter will be construed as granting the American Academy of Family Physicians permission to publish the letter in any of its publications in any form. The editors may edit letters to meet style and space requirements.



Copyright © 2003 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

Navigate this Article